Skip to content

Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen

Evaluation of Efficacy and Safety of Subcutaneous Acetaminophen in Geriatrics and Palliative Care

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03635684
Acronym
APAPSubQ
Enrollment
31
Registered
2018-08-17
Start date
2018-05-17
Completion date
2020-06-01
Last updated
2020-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Effect, Drug Reaction, Fever, Pain

Keywords

Acetaminophen, Palliative Care, Infusions, Subcutaneous, Treatment Outcome, Geriatrics, Gerontology

Brief summary

Subcutaneous perfusion is an underused technique, the effectiveness of which has been demonstrated. A number of drugs of different therapeutic classes, including morphine, have a good level of scientific evidence for use by this route. Subcutaneous Acetaminophen injection is being used in some medical centers, mainly in Europe, despite the lack of definite evidence on its efficacy. This study aims to quantify the degree of effectiveness of subcutaneous Acetaminophen infusions for pain or fever in Geriatrics and Palliative Care, as well as determining its safety.

Detailed description

Subcutaneous perfusion is an underused technique, the effectiveness of which has been demonstrated. It is mainly used in Palliative Care and Geriatrics when a venous line is not available. It is a simple and comfortable technique that allows to administer solutes and / or medications continuously or discontinuously in the subcutaneous tissue. A number of drugs of different therapeutic classes, including morphine, have a good level of scientific evidence for use by this route. Subcutaneous Acetaminophen injection is being used in some medical centers, mainly in Europe, despite the lack of definite evidence on its efficacy. It is sometimes accused of causing pain at the injection site; it seems that this is not the case if it is infused slowly, over 20 minutes to 30 minutes. There is no report of serious local effects. The consultation palliative care team at Hôtel-Dieu de France (HDF) has used subcutaneous Acetaminophen infusions repeatedly without adverse effects since January 2014. This study aims to quantify the degree of effectiveness of subcutaneous Acetaminophen infusions for pain or fever in Geriatrics and Palliative Care, as well as determining its safety.

Interventions

DRUGAcetaminophen

Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of: * local side effects; * pain and/or fever; at time of infusion, after 30 minutes, 60 minutes and 180 minutes.

Sponsors

Saint-Joseph University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients seen by the Palliative Care Consultation Team, patients admitted in the Palliative Care Unit, or Geriatric patients (patients aged 65 and older) in participating centers in Lebanon * Presence of pain or fever necessitating the administration of Paracetamol * Absence of an Intravenous Line

Design outcomes

Primary

MeasureTime frameDescription
Change in Numerical Rating Scale pain scores for conscious and cooperative patients60 minutesThis outcome measures the decrease in pain scores between t0 (right before acetaminophen administration) and t60 minutes using the Numerical Rating Scale in conscious and cooperative patients, where 10/10 is the worst imaginable pain and 0/10 is no pain at all. A Minimal Clinically Important Difference (MCID) of 2/10 is set to define efficacy.
Change on Algoplus Pain Scale for patients with verbal communication difficulties60 minutesThis outcome measures the decrease in pain scores between t0 (right before acetaminophen administration) and t60 minutes using Algoplus Scale, a behavioural rating scale for acute pain for patients with verbal communication difficulties. A score of 2 or above diagnoses pain with 87% sensitivity and 80% specificity. The scale evaluates facial expressions, look, complaints, body position and atypical behaviours of patients with verbal communication difficulties. Each item marked yes is awarded one point and the total across all the items gives a total score out of 5. Efficacy is defined as a decrease of the score to less than 2/5.
Change in temperature measurement60 minutesDecrease in temperature measurement. A Minimal Clinically Important Difference (MCID) of 0.5 degrees Celsius is set to define efficacy.
Appearance of local side effectsat the time of perfusion, after 30 minutes, 60 minutes and 180 minutes, and one day after line removalAny local side effect is reported, including: * edema, * induration, * erythema, * tenderness, * warmth, * abcess, * necrosis

Secondary

MeasureTime frameDescription
Early effect on fever30 minutesTo evaluate if any early effect on fever is measurable, temperature is measured at t30 minutes.
Early effect on pain in conscious and cooperative patients30 minutesTo evaluate if any early effect on pain is measurable, this outcome measures the pain scores at t30 minutes using the Numerical Rating Scale in conscious and cooperative patients, where 10/10 is the worst imaginable pain and 0/10 is no pain at all.
Sustained effect on fever180 minutesTo evaluate if the effect on fever is sustained over time, temperature is measured at t180 minutes
Sustained effect on pain in conscious and cooperative patients180 minutesTo evaluate if the effect on pain is sustained over time, this outcome measures the pain scores at t180 minutes using the Numerical Rating Scale in conscious and cooperative patients, where 10/10 is the worst imaginable pain and 0/10 is no pain at all.
Early effect on pain in patients with verbal communication difficulties30 minutesTo evaluate if any early effect on pain is measurable, this outcome measures the pain scores at t60 minutes and t180 minutes using Algoplus Scale, a behavioural rating scale for acute pain for patients with verbal communication difficulties. A score of 2 or above diagnoses pain with 87% sensitivity and 80% specificity. The scale evaluates facial expressions, look, complaints, body position and atypical behaviours of patients with verbal communication difficulties. Each item marked yes is awarded one point and the total across all the items gives a total score out of 5.
Sustained effect on pain in patients with verbal communication difficulties180 minutesTo evaluate if the effect on pain is sustained over time, this outcome measures the pain scores at t180 minutes using Algoplus Scale, a behavioural rating scale for acute pain for patients with verbal communication difficulties. A score of 2 or above diagnoses pain with 87% sensitivity and 80% specificity. The scale evaluates facial expressions, look, complaints, body position and atypical behaviours of patients with verbal communication difficulties. Each item marked yes is awarded one point and the total across all the items gives a total score out of 5.

Countries

Lebanon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026